ARIMIDEX SHOULD BE PREFERRED FIRST-LINE THERAPY IN POSTMENOPAUSAL ...
20386
AstraZeneca Plcâs aromatase inhibitor Arimidex (anastrozole) is superior to tamoxifen for the treatment of postmenopausal women with localized, hormone-receptor-positive breast cancer, and a five-year course of the drug should be considered the
180700
A group of drugs called aromatase inhibitors should be used after surgery to treat postmenopausal women with hormone-receptor-positive breast cancer, new guidelines recommend.
202457
Older women with breast cancer are being encouraged to use a new drug which is better at preventing re-occurrence of the disease, has fewer side effects - but costs Â£1,000 a year instead of Â£30.
329902
A new drug may give older women with early stages of breast cancer a better chance of beating the disease and stopping it returning and spreading.
243868
A newer drug called anastrozole could replace tamoxifen as the standard drug for postmenopausal breast cancer patients whose cancer is fueled by estrogen, a new study finds.
446242
Raloxifene (Evista) continues to be associated with more than a 50% reduction in breast cancer incidence beyond the first 4 years of treatment, according to a new study in the December 1 issue of the Journal of the National Cancer Institute.
708975
NEW YORK  - Treating rheumatoid arthritis with "biologic" immunosuppressive drugs, such as TNF-blockers, neither increases nor decreases the risk of heart attack or stroke compared with use of methotrexate, the most commonly prescribed drug for rheumatoid arthritis, new research indicates.
501881
Shorter courses of chemotherapy taken with Roche Holding AG's cancer drug MabThera are as effective as longer courses in elderly patients with aggressive lymphoma, a study in The Lancet Oncology showed.
397182
SAN ANTONIO - Dec. 9, 2004 â-esults of an ogoing study show that a new class of drug called aromatase inhibitors can cut the rate of breast cancer recurrence by 76 percent in certain older women.
339523
-- For women who have struggled with the symptoms of menopause but are fearful of taking risky hormone pills, there is at last a bit of hope.
609109
FRIDAY, Sept. 14 (HealthDay News) -- The Eli Lilly drug Evista (raloxifene) has been approved by the U.S. Food and Drug Administration to reduce the risk of invasive breast cancer among postmenopausal at high risk for the disease and among postmenopausal women with osteoporosis.
399636
A drug currently used against advanced breast cancer may provide better protection against recurrence or spreading than standard medication for post-menopausal women who have been treated for early forms of the disease, Swiss pharmaceutical giant Novartis AG and independent researchers said Wednesday.
414428
WASHINGTON - Despite its clear risks and bad press, hormone therapy remains the best treatment for some women suffering miserable menopause symptoms - and it is inappropriate for doctors to withhold, says a new guide to help doctors and patients with the difficult decision.    Women who do try estrogen should use the lowest possible dose for the shortest period of time, the American College of Obstetricians and Gynecologists stressed...
43000
A class of hormone-blocking drugs called aromatase inhibitors was more effective in preventing breast cancer recurrence in women past menopause than was tamoxifen, a medication now prescribed
28356
Boston researchers say many women at high risk for breast cancer are declining tamoxifen, the first approved drug for prevention of breast cancer.
482773
NEW YORK  - There appears to be no  substantial increase in hot flashes in postmenopausal women who  are treated with raloxifene, sold as Evista, for osteoporosis  treatment and prevention, according to a report in the American  Journal of Obstetrics and Gynecology.
237585
Drug therapy given before the  primary chemotherapy for breast cancer does not appear to  worsen mental processes, or &quot;cognitive function,&quot; German  investigators report in the journal Cancer. Suspicions that it  does may have been influenced by cases of mental decline that  occurred before treatment began.